Clinical & Experimental Metastasis

, Volume 28, Issue 5, pp 413–425 | Cite as

Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma

  • Ying-Fu Liu
  • Peng-Fei Zhang
  • Mao-Yu Li
  • Quo-Qing Li
  • Zhu-Chu Chen
Research Paper


Metastasis is the most common cause of death in lung cancer patients and is a major obstacle to the successful treatment. To discover novel metastasis-related proteins in lung adenorcinoma (AdC), quantitative proteomic analysis was performed between primary lung AdC tissues with (LNM AdC) and without lymph node metastasis (non-LNM AdC). In this study, annexin A1 was identified to be significantly up-regulated in LNM AdC compared with non-LNM AdC. Immunohistochemistry showed that annexin A1 over-expression was frequently observed in LNM AdCs and matched lymph node metastases compared with non-LNM AdCs. Annexin A1 over-expression was significantly associated with advanced clinical stage (P < 0.05) and lymph node metastasis (P < 0.05) and increased relapse rate (P < 0.05) and decreased overall survival (P < 0.05) in lung AdCs. Cox regression analysis indicated annexin A1 over-expression was an independent prognostic factor. Furthermore, suppression of annexin A1 expression by siRNA interference significantly inhibited the invasion ability of lung adenocarcinoma cell A549 in vitro. In conclusion, annexin A1 expression correlated with tumor stage, lymph node metastasis, relapse, and patient survival. Annexin A1 is proposed to function importantly in the progression of lung AdC.


Annexin A1 Lung adenocarcinoma Proteomics Invasion Prognostic factor 


Lung AdC

Lung adenocarcinoma


Lymph node metastasis


Lung adenocarcinoma without lymph node metastasis


Lung adenocarcinoma with lymph node metastasis


Two-dimensional difference gel electrophoresis

Positive LN

Positive lymph node


Hazard ratio


Confidence interval



This work was supported by grants from National Key Basic Research Program of China (2001CB510207), the Fundamental Research Funds for the Central Universities (2010121104) and Outstanding Scholars of New Era from Ministry of Education of China (2002-48).

Conflicts of interest

No conflicts of interest are declared.


  1. 1.
    Little AG et al (2007) National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 57(3):253–260PubMedCrossRefGoogle Scholar
  2. 2.
    Liao ML et al (2007) Incidence, time trend, survival, and predictive factors of lung cancer in Shanghai populations. Zhonghua Yi Xue Za Zhi 87(27):1876–1880PubMedGoogle Scholar
  3. 3.
    Jemal A et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106-30Google Scholar
  4. 4.
    Giese A et al (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21(8):1624–1636PubMedCrossRefGoogle Scholar
  5. 5.
    Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer 80(8 Suppl):1529–1537PubMedCrossRefGoogle Scholar
  6. 6.
    Kohn EC (1993) Development and prevention of metastasis. Anticancer Res 13(6B):2553–2559PubMedGoogle Scholar
  7. 7.
    Fidler IJ, Kripke ML (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197(4306):893–895PubMedCrossRefGoogle Scholar
  8. 8.
    Steeg PS et al (1988) Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80(3):200–204PubMedCrossRefGoogle Scholar
  9. 9.
    Chen JJ et al (2001) Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 61(13):5223–5230PubMedGoogle Scholar
  10. 10.
    Van den Bergh G, Arckens L (2004) Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Curr Opin Biotechnol 15(1):38–43PubMedCrossRefGoogle Scholar
  11. 11.
    Yan JX et al (2002) Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of Escherichia coli. Proteomics 2(12):1682–1698PubMedCrossRefGoogle Scholar
  12. 12.
    Di Rosa M et al (1984) Anti-phospholipase proteins. Prostaglandins 28(4):441–442PubMedCrossRefGoogle Scholar
  13. 13.
    Wallner BP et al (1986) Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature 320(6057):77–81PubMedCrossRefGoogle Scholar
  14. 14.
    Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82(2):331–371PubMedGoogle Scholar
  15. 15.
    Rescher U, Gerke V (2004) Annexins—unique membrane binding proteins with diverse functions. J Cell Sci 117(Pt 13):2631–2639PubMedCrossRefGoogle Scholar
  16. 16.
    Brichory FM et al (2001) An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 98(17):9824–9829PubMedCrossRefGoogle Scholar
  17. 17.
    Wang KL et al (2006) Expression of Annexin A1 in Esophageal and Esophagogastric Junction Adenocarcinomas: Association with Poor Outcome. Clin Cancer Res 12(15):4598–4604PubMedCrossRefGoogle Scholar
  18. 18.
    Lim LH, Pervaiz S (2007) Annexin 1: the new face of an old molecule. Faseb J 21(4):968–975PubMedCrossRefGoogle Scholar
  19. 19.
    Emoto K et al (2001) Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 92(6):1419–1426PubMedCrossRefGoogle Scholar
  20. 20.
    Yang YX et al (2006) Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 6(6):2009–2021PubMedCrossRefGoogle Scholar
  21. 21.
    Yang F et al (2007) Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 6(2):751–758PubMedCrossRefGoogle Scholar
  22. 22.
    Cheng A-L et al (2008) Identification of Novel Nasopharyngeal Carcinoma Biomarkers by Laser Capture Microdissection and Proteomic Analysis. Clin Cancer Res 14(2):435–445PubMedCrossRefGoogle Scholar
  23. 23.
    Tian T et al (2007) Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci 98(8):1265–1274PubMedCrossRefGoogle Scholar
  24. 24.
    Chang GC et al (2006) Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 12(19):5746–5754PubMedCrossRefGoogle Scholar
  25. 25.
    Chen G et al (2003) Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 100(23):13537–13542PubMedCrossRefGoogle Scholar
  26. 26.
    Arai K et al (2001) Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation. Oncol Rep 8(3):591–596PubMedGoogle Scholar
  27. 27.
    El-Rifai W et al (2002) Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62(23):6823–6826PubMedGoogle Scholar
  28. 28.
    Hermani A et al (2005) Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 11(14):5146–5152PubMedCrossRefGoogle Scholar
  29. 29.
    Oremek G et al (2007) The significance of TU M2-PK tumor marker for lung cancer diagnostics. Klin Med (Mosk) 85(7):56–58Google Scholar
  30. 30.
    Hathurusinghe HR, Goonetilleke KS, Siriwardena AK (2007) Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann Surg Oncol 14(10):2714–2720PubMedCrossRefGoogle Scholar
  31. 31.
    Weinberger R et al (2007) The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma. Eur J Cancer Care (Engl) 16(4):333–337CrossRefGoogle Scholar
  32. 32.
    Ahmed AS et al (2007) M2-PK as a novel marker in ovarian cancer. A prospective cohort study. Eur J Gynaecol Oncol 28(2):83–88PubMedGoogle Scholar
  33. 33.
    Chen ZG (2007) Exploration of metastasis-related proteins as biomarkers and therapeutic targets in the treatment of head and neck cancer. Curr Cancer Drug Targets 7(7):613–622PubMedCrossRefGoogle Scholar
  34. 34.
    Liang L, Qu L, Ding Y (2007) Protein and mRNA characterization in human colorectal carcinoma cell lines with different metastatic potentials. Cancer Invest 25(6):427–434PubMedCrossRefGoogle Scholar
  35. 35.
    Tomonaga T et al (2004) Identification of Altered Protein Expression and Post-Translational Modifications in Primary Colorectal Cancer by Using Agarose Two-Dimensional Gel Electrophoresis. Clin Cancer Res 10(6):2007–2014PubMedCrossRefGoogle Scholar
  36. 36.
    Babbin BA et al (2006) Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem 281(28):19588–19599PubMedCrossRefGoogle Scholar
  37. 37.
    Dai Z et al (2006) Identification and analysis of altered alpha1, 6-fucosylated glycoproteins associated with hepatocellular carcinoma metastasis. Proteomics 6(21):5857–5867PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Department of Basic Medical Sciences, Medical CollegeXiamen UniversityXiamenChina
  2. 2.Key Laboratory of Cancer Proteomics of Ministry of HealthCentral South UniversityChangshaChina

Personalised recommendations